We are live on ! Find out more
LYRA

LYRA THERAPEUTICS INC
LYRA

Delisted

LYRA was delisted on the 16th of March, 2026.

Back to rankings

31 hedge funds and large institutions have $38.1M invested in LYRA THERAPEUTICS INC in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more call options, than puts

Call options by funds: $9K | Put options by funds: $1K

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.01% less ownership

Funds ownership: 1.2% → 1.19% (-0.01%)

11% less funds holding

Funds holding: 35 → 31 (-4)

36% less capital invested

Capital invested by funds: $59.9M → $38.1M (-$21.8M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
4
Closed
5
Calls
$9K
Puts
$1K
Net Calls
+$8K
Net Calls Change
-$28K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$144K
2
Squarepoint
Squarepoint
New York
+$28K
3
Renaissance Technologies
Renaissance Technologies
New York
+$26.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$12.8K
5
Bank of America
Bank of America
North Carolina
+$7.43K

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$397K
2
AFM
Anson Funds Management
Texas
-$123K
3
Citadel Advisors
Citadel Advisors
Florida
-$43K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$42.6K
5
BAM
Belpointe Asset Management
Nevada
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$18.4M – – –
NCM
2
Nantahala Capital Management
Connecticut
$4.46M – – –
PVI
3
Pura Vida Investments
New York
$4.01M -$397K -3,207 -7%
SB
4
Samsara BioCapital
California
$3.57M – – –
VA
5
VR Adviser
New York
$1.86M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.59M – – –
SCM
7
Soleus Capital Management
Connecticut
$1.19M – – –
IC
8
Ikarian Capital
Texas
$711K – – –
Ensign Peak Advisors
9
Ensign Peak Advisors
Utah
$626K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$308K – – –
BCM
11
Bridgeway Capital Management
Texas
$304K – – –
CC
12
Clearline Capital
New York
$239K – – –
Bank of America
13
Bank of America
North Carolina
$211K +$7.43K +60 +3%
Millennium Management
14
Millennium Management
New York
$120K +$144K +1,162 New
Renaissance Technologies
15
Renaissance Technologies
New York
$96K +$26.4K +213 +29%
BlackRock
16
BlackRock
New York
$83.2K +$3.22K +26 +3%
State Street
17
State Street
Massachusetts
$77.8K – – –
BFM
18
Boothbay Fund Management
New York
$69.8K – – –
Northern Trust
19
Northern Trust
Illinois
$60K – – –
Two Sigma Advisers
20
Two Sigma Advisers
New York
$56.9K -$744 -6 -1%
Squarepoint
21
Squarepoint
New York
$23.4K +$28K +226 New
TRCT
22
Tower Research Capital (TRC)
New York
$20K +$12.8K +103 +107%
Citadel Advisors
23
Citadel Advisors
Florida
$16.4K -$43K -347 -69%
UBS Group
24
UBS Group
Switzerland
$1.71K -$6.32K -51 -75%
AWM
25
Ameliora Wealth Management
Switzerland
$1.55K – – –
1
2

LYRA Hedge Fund Activity: Q1 2023 in Review

31 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q1 2023, worth a combined $38.1M — down 36% from $59.9M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of LYRA and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $144K. The largest seller was Pura Vida Investments, cutting an estimated $397K.

  • 31 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q1 2023, down from 35 in Q4 2022.
  • Funds reported $38.1M of LYRA THERAPEUTICS INC stock for Q1 2023, down 36% quarter-over-quarter.
  • 2 funds opened new LYRA THERAPEUTICS INC positions in Q1 2023 and 5 closed out, a net change of -3 holders.
  • The largest LYRA THERAPEUTICS INC buyer in Q1 2023 was Millennium Management, an estimated $144K added.
  • The largest LYRA THERAPEUTICS INC seller in Q1 2023 was Pura Vida Investments, an estimated $397K sold.

Based on aggregated 13F filings for Q1 2023.